These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
857 related articles for article (PubMed ID: 20346867)
1. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors. Okarvi SM; Al Jammaz I Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867 [TBL] [Abstract][Full Text] [Related]
2. Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics. Okarvi SM; Jammaz IA Nucl Med Biol; 2012 Aug; 39(6):795-804. PubMed ID: 22381782 [TBL] [Abstract][Full Text] [Related]
3. Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent. Okarvi SM; al-Jammaz I Anticancer Res; 2003; 23(3B):2745-50. PubMed ID: 12894569 [TBL] [Abstract][Full Text] [Related]
4. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical. Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305 [TBL] [Abstract][Full Text] [Related]
5. Impact of functionalized coligands on the pharmacokinetics of 99mTcIII '4+1' mixed-ligand complexes conjugated to bombesin. Kunstler JU; Bergmann R; Gniazdowska E; Koźmiński P; Walther M; Pietzsch HJ J Inorg Biochem; 2011 Nov; 105(11):1383-90. PubMed ID: 21946438 [TBL] [Abstract][Full Text] [Related]
6. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties. Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer. Okarvi SM; Jammaz IA Anticancer Res; 2009 Apr; 29(4):1399-409. PubMed ID: 19414394 [TBL] [Abstract][Full Text] [Related]
8. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619 [TBL] [Abstract][Full Text] [Related]
9. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Faintuch BL; Teodoro R; Duatti A; Muramoto E; Faintuch S; Smith CJ Nucl Med Biol; 2008 May; 35(4):401-11. PubMed ID: 18482677 [TBL] [Abstract][Full Text] [Related]
10. Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores. Decristoforo C; Santos I; Pietzsch HJ; Kuenstler JU; Duatti A; Smith CJ; Rey A; Alberto R; Von Guggenberg E; Haubner R Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):33-41. PubMed ID: 17372571 [TBL] [Abstract][Full Text] [Related]
12. Structural modifications of ⁹⁹mTc-labelled bombesin-like peptides for optimizing pharmacokinetics in prostate tumor targeting. Liolios CC; Fragogeorgi EA; Zikos C; Loudos G; Xanthopoulos S; Bouziotis P; Paravatou-Petsotas M; Livaniou E; Varvarigou AD; Sivolapenko GB Int J Pharm; 2012 Jul; 430(1-2):1-17. PubMed ID: 22459664 [TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of the tumor-specific antigen-derived synthetic mucin 1 peptide: A potential candidate for the targeting of breast carcinoma. Okarvi SM; Al Jammaz I Nucl Med Biol; 2016 Jul; 43(7):403-9. PubMed ID: 27179249 [TBL] [Abstract][Full Text] [Related]
14. [(99m)Tc]Demomedin C, a radioligand based on human gastrin releasing peptide(18-27): synthesis and preclinical evaluation in gastrin releasing peptide receptor-expressing models. Nock BA; Cescato R; Ketani E; Waser B; Reubi JC; Maina T J Med Chem; 2012 Oct; 55(19):8364-74. PubMed ID: 22966957 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging. Zhou Z; Wagh NK; Ogbomo SM; Shi W; Jia Y; Brusnahan SK; Garrison JC J Nucl Med; 2013 Sep; 54(9):1605-12. PubMed ID: 23896558 [TBL] [Abstract][Full Text] [Related]
17. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. Cescato R; Maina T; Nock B; Nikolopoulou A; Charalambidis D; Piccand V; Reubi JC J Nucl Med; 2008 Feb; 49(2):318-26. PubMed ID: 18199616 [TBL] [Abstract][Full Text] [Related]
18. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066 [TBL] [Abstract][Full Text] [Related]
19. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. Maina T; Nock BA; Zhang H; Nikolopoulou A; Waser B; Reubi JC; Maecke HR J Nucl Med; 2005 May; 46(5):823-30. PubMed ID: 15872357 [TBL] [Abstract][Full Text] [Related]
20. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]